tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
1.160USD
+0.010+0.87%
收盘 02/09, 16:00美东报价延迟15分钟
35.40M总市值
亏损市盈率 TTM

Telomir Pharmaceuticals Inc

1.160
+0.010+0.87%

关于 Telomir Pharmaceuticals Inc 公司

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc简介

公司代码TELO
公司名称Telomir Pharmaceuticals Inc
上市日期Feb 09, 2024
CEOAminov (Erez)
员工数量- -
证券类型Ordinary Share
年结日Feb 09
公司地址900 West Platt Street, Suite 200
城市TAMPA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33606
电话18138642562
网址https://telomirpharma.com/
公司代码TELO
上市日期Feb 09, 2024
CEOAminov (Erez)

Telomir Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+979885.00%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+979885.00%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 2月8日 周日
更新时间: 2月8日 周日
持股股东
股东类型
持股股东
持股股东
占比
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.31%
其他
56.24%
持股股东
持股股东
占比
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.31%
其他
56.24%
股东类型
持股股东
占比
Corporation
29.82%
Individual Investor
15.16%
Investment Advisor
5.07%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.68%
Research Firm
0.13%
其他
48.09%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
106
2.38M
6.93%
-810.98K
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Bay Shore Trust
6.73M
19.58%
-89.00K
-1.30%
Dec 31, 2024
Mira Pharmaceuticals, Inc
3.52M
10.24%
+3.52M
--
Sep 29, 2025
McNulty (Brian Patrick)
1.88M
5.46%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.16%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.10M
3.2%
-16.47K
-1.47%
Sep 30, 2025
Aminov (Erez)
1.01M
2.94%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.42%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
287.80K
0.84%
-69.21K
-19.39%
Sep 30, 2025
Millennium Management LLC
222.40K
0.65%
-25.30K
-10.21%
Sep 30, 2025
Geode Capital Management, L.L.C.
196.03K
0.57%
-850.00
-0.43%
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
占比0.01%
iShares Russell 2000 ETF
占比0%
Global X Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI